Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of the 87 participants

From: Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria

 A1A2A3P value
n462516 
Sex (male/female)21/2516/910/60.251
Age (years)67.0 ± 8.966.8 ± 7.063.3 ± 8.90.287
Body mass index (kg/m2)29.8 ± 6.729.0 ± 4.228.3 ± 4.20.632
Body weight (kg)75.5 ± 18.676.9 ± 13.474.0 ± 12.20.859
Duration of diabetes (years)14.6 ± 6.715.8 ± 7.618.0 ± 8.80.284
HbA1c (%)7.1 ± 0.77.2 ± 0.87.8 ± 1.0 *0.015
eGFR (mL/min/1.73 m2)47.2 ± 8.748.5 ± 8.842.5 ± 9.60.105
Category of GFR (G3a/G3b/G4)27/18/118/6/19/6/10.681
Systolic blood pressure (mmHg)127.6 ± 8.9130.6 ± 11.5131.2 ± 10.80.323
Diastolic blood pressure (mmHg)74.3 ± 7.772.9 ± 10.673.8 ± 7.10.813
ARB or ACE-I (%)82.696.0100.0 
SGLT2 inhibitor (%)
 Canagliflozin23.912.037.5 
 Dapagliflozin13.08.06.3 
 Empagliflozin8.74.012.5 
 Ipragliflozin4.320.018.8 
 Luseogliflozin6.520.06.3 
 Tofogliflozin43.536.018.8 
Other oral hypoglycemic agents (%)
 Sulfonylurea50.052.062.5 
 Biguanide71.780.093.8 
 Thiazolidinedione2.28.014.3 
 Alpha-glucosidase inhibitor15.020.00.0 
 Glinide0.00.00.0 
 DPP-4 inhibitor50.076.062.5 
Insulin (%)13.012.025.0 
  1. Values are expressed as mean ± SD
  2. ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, DPP-4 dipeptidyl peptidase-4, eGFR estimated glomerular filtration rate, SGLT2 sodium–glucose cotransporter 2
  3. *P < 0.05 vs. A1 group